🔗 Share this article

While America undertakes historic revisions to its vaccine recommendations, a particular individual has surfaced in a surprising turn: Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccines throughout the global health crisis and has focused upon possible deaths following Covid immunization in her brief tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Health officials had intended to reveal sweeping revisions to the pediatric vaccination calendar recently, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with much of the international standard with no evidence for public health gain. This reveal has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A Shift at the FDA

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric immunization guidelines in the US to become more in line with the Danish model, a society with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Qualifications

The appointee has no obvious track record in medication creation, oversight or leadership, which has been standard for former leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a major agency. She lacks background in drug approvals.”

Former directors of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that former directors who led CBER have had.”

CDER has an immense workload at the FDA, Woodcock pointed out.

“Everybody just focuses on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and more, and all of those need to be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major leadership component to the position, which manages more than 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” Woodcock added.

Response and Controversial Initiatives

Regarding questions about Høeg’s fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a press secretary stated that the “questions are based on inaccurate presumptions”.

“This background is consistent with the duties of her job,” the representative explained, citing the months Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that apparently worried her predecessors. “By what process are these drugs being picked for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he said, “the agency seems to be moving towards less stringent rules of all drugs, with the exception of shots.”

Documented Past Work on Vaccines

With immunizations, Høeg has a more established, if concerning, past, Howard have noted. She authored a study using unverified public submissions to estimate the rate of myocarditis after Covid immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the incoming federal leadership included altering guidelines for novel immunizations and halting “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Dr. Høeg has allegedly floated the idea of preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an complete true believer who starts off with her beliefs and tailors the evidence to accommodate the data in a highly misleading, dishonest way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|